The logistical considerations surrounding COVID-19 testing has become a part of the weekly routine for orthopedic surgeons. Although it is rare for patients to become COVID-19 positive, owing to scheduled osteochondral allograft (OCA) or the second stage of autologous chondrocyte implantation (ACI), it poses a problem when considering delivery of the expensive tissues. Mass vaccination drives are anticipated to reduce the burden of logistical and other regulatory restrictions.
Preventive measures, optimized manufacturing protocols, and post-graft release management options are growing popular in the soft tissue market. Stakeholders in the soft tissue market are increasing their communication between the surgical team and graft providers as a part of their optimized manufacturing protocols. Safe return of grafts, alternative options before wasting graft, and knowledge of liability for cost of grafts are being taken into consideration.
Companies Diverting Production Activities toward Artificial Scaffolds Due to Allograft Limitations
Allografts and xenografts are overcoming the limitations of autografts where the latter is subject to limited availability and donor-site morbidity. However, even allografts are prone to trigger immune rejection and disease transmission. Moreover, their osteoinductive potential is frequently impaired due to disruptive processing. Hence, companies in the soft tissue market are now increasing their research in alternative approaches with the help of artificial scaffolds that are specifically-designed to maintain physical integrity and promote bone ingrowth at the defect site.
Despite promising results in research for smart formulations to support improved control over growth factor release to bone regeneration sites, several of these ambitious materials are found to be limited only up to the animal study stage. As such, most of the activated devices that are being commercialized in clinics are based in allografts or collagen/tricalcium phosphate scaffolds. This is evident since collagen allografts are predicted to dominate the highest revenue share among all product types in the market during the assessment period.
The soft tissue market is expected to reach US$ 8.6 Bn by 2031. The custom 3D bone allograft block fabrication is a fast growing phenomenon in the market, as the digital technology has drastically improved all areas of modern medicine and will continue to do so in the upcoming decade. Growing demand for accurate treatment planning, decline in patient chair-side time, and greater surgical accuracy have fueled the demand for custom 3D bone allografts in the modern implant dentistry. Companies in the soft tissue market are taking advantage of such developments to gain a strong research base in platelet-rich fibrin (PRF), which is being favored in regenerative dentistry.
Tendon allografts hold promising potentials in ligament reconstruction procedures. Companies in the soft tissue market are increasing their production capacities in tendon allografts, since they simplify the surgical technique by negating the need to harvest autograft, whilst eliminating issues associated with donor site morbidity. Allograft tissue specialists, Hospital Innovations, are building their product portfolio in bone & BTB (bone–patellar tendon–bone) tendon allografts that help to accommodate multiple techniques and fixation options in primary & revision ligament reconstructions.
Manufacturers in the soft tissue market are also innovating in non-bone tendon allografts that are an excellent alternative to autograft for any ligament reconstruction procedure. High quality non-bone tendon allografts have the ability to accurately size match and allows the surgeon with flexibility to perform a variety of surgical techniques.
Apart from tendon and collagen allografts, companies in the soft tissue market are innovating in amniotic allografts. Surgenex® is gaining recognition as a producer and distributor of the highest quality of amniotic membrane tissue allograft in the healthcare industry. Manufacturers are taking cues from such innovations to increase the availability of amniotic allografts that are lightweight and flexible. This helps to provide a protective covering, offer ease of use, and reduce bulk at the site.
Unparalleled quality standards and serological testing are helping manufacturers in the soft tissue market to gain the FDA approval for products. Manufacturers are adopting processes that extract the membrane from the placental tissue, leaving only the amniotic membrane layer, which is dehydrated into a sheet-like product. Immunological properties in amniotic membranes help to offer benefits in regenerative medicine.
Osteochondral lesions are a tear or a fracture that involve damage to both the cartilage and underlying bone. Locate Bio - an orthobiologics-focused regenerative medicine company, has received the Breakthrough Device Designation from the U.S. FDA (Food and Drug Administration) for its biomimetic graft Chondro3 meant for osteochondral lesions.
The increasing number of knee arthroscopies performed in the U.S. each year involves a chondral lesion, which is translating into revenue opportunities for manufacturers in the global soft tissue market. Regenerative biomimetic grafts are being designed to address this growing unmet clinical need. Proprietary designs involving three-layered collagen-based biodegradable matrix that can be delivered in a single procedure are being preferred by clinicians. Manufacturers are increasing the availability of affordable biomimetic grafts that can be useful in outpatient settings.
Companies in the soft tissue market are bolstering their output capabilities in innovative cellular and tissue allografts to help surgeons heal their patients. AlloSource® - an allografts provider in the U.S. has announced that it is naming its new cellular and tissue allografts under the new brand AlloConnex™.
Tendon and ligament transplantation is being carried out through skilled hands of surgeons. Manufacturers in the soft tissue market are building their portfolio in tendon and ligament allografts to support a multitude of procedures that surgeons perform to connect patients back to their active lifestyles. They are increasing the availability of single strand, double strand double bundle, and pre-shaped configurations in tendon and ligament allografts that help to heal severe burns.
Analysts’ Viewpoint
The optimization of the logistical aspects of autologous cultured chondrocytes on porcine collagen membrane (MACI) and osteochondral allograft (OCA) surgery is becoming paramount amid the COVID-19 outbreak to avoid graft wastage. Implant surgeons are adopting custom printing 3D surgical guides in-office, following a plethora of growing courses available on the topic. The soft tissue market is slated to clock a favorable CAGR of ~7% during the forecast period. However, raw materials for tissue grafts require extensive screening to reduce the risk of disease transmission. Thus, to achieve this, stakeholders should process materials under strict cGMP (Current Good Manufacturing Practice) or ISO standards to ensure the safety, reproducibility, and scalability of the process.
Soft Tissue Market – Segmentation
TMR’s study on the global soft tissue market includes information divided into three segments: product type, end user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global soft tissue market are discussed in detail.
| Product Type |
|
| End User |
|
| Region |
|
The global soft tissue market was worth US$ 4.3 Mn and is projected to reach a value of US$ 8.59 Bn by the end of 2031
Soft tissue market is anticipated to grow at a CAGR of 7% during the forecast period
North America accounted for a major share of the global soft tissue market
The global soft tissue market is driven by better quality alternatives to autografts and technological advancements
Key players in the global soft tissue market include Corneat Vision, LinkoCare Life Sciences AB, Presbia plc, Bone Bank Allografts, MTF Biologics, CONMED Corporation, AlloSource, Arthrex, Inc., Zimmer Biomet Holdings, Inc., and RTI Surgical, Inc.
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Global Soft Tissue Market Forecast
4.4. Global Soft Tissue Market Outlook
5. Market Outlook
5.1. Key Industry Events
5.2. Product Pricing Analysis, by Region
5.3. Impact of COVID-19 Pandemic
6. Global Soft Tissue Market Analysis, by Product Type
6.1. Introduction
6.2. Global Soft Tissue Market Value Share Analysis, by Product Type
6.3. Global Soft Tissue Market Forecast, by Product Type
6.3.1. Cartilage Allografts
6.3.2. Tendon Allografts
6.3.2.1. Achilles Tendon
6.3.2.2. Patellar Tendon
6.3.2.3. Others
6.3.3. Meniscus
6.3.4. Ligament Allografts
6.3.4.1. Anterior Cruciate Ligament
6.3.4.2. Medial Collateral ligament
6.3.5. Artificial Cornea
6.3.6. Dental Allografts
6.3.7. Collagen Allografts
6.3.8. Amniotic Allografts
6.4. Global Soft Tissue Market Analysis, by Product Type
6.5. Global Soft Tissue Market Attractiveness Analysis, by Product Type
7. Global Soft Tissue Market Analysis, by End-user
7.1. Introduction
7.2. Global Soft Tissue Market Value Share Analysis, by End-user
7.3. Global Soft Tissue Market Forecast, by End-user
7.3.1. Hospitals
7.3.2. Orthopedic Clinics
7.3.3. Others
7.4. Global Soft Tissue Market Analysis, by End-user
7.5. Global Soft Tissue Market Attractiveness Analysis, by End-user
8. Global Soft Tissue Market Analysis, by Region
9. Global Soft Tissue Market Analysis, by Region
9.1. Global Soft Tissue Market Value Share Analysis, by Region
9.2. Global Soft Tissue Market Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
10. North America Soft Tissue Market Analysis
10.1. North America Soft Tissue Market Overview
10.2. North America Soft Tissue Market Value Share and Attractiveness Analysis, by Country
10.3. North America Soft Tissue Market Forecast, by Country
10.3.1. U.S.
10.3.2. Canada
10.4. North America Soft Tissue Market Value Share and Attractiveness Analysis, by Product Type
10.5. North America Soft Tissue Market Forecast, by Product Type
10.5.1. Cartilage Allografts
10.5.2. Tendon Allografts
10.5.2.1. Achilles Tendon
10.5.2.2. Patellar Tendon
10.5.2.3. Others
10.5.3. Meniscus
10.5.4. Ligament Allografts
10.5.4.1. Anterior Cruciate Ligament
10.5.4.2. Medial Collateral ligament
10.5.5. Artificial Cornea
10.5.6. Dental Allografts
10.5.7. Collagen Allografts
10.5.8. Amniotic Allografts
10.6. North America Soft Tissue Market Value Share and Attractiveness Analysis, by End-user
10.7. North America Soft Tissue Market Forecast, by End-user
10.7.1. Hospitals
10.7.2. Orthopedic Clinics
10.7.3. Others
11. Europe Soft Tissue Market Analysis
11.1. Europe Soft Tissue Market Overview
11.2. Europe Soft Tissue Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Europe Soft Tissue Market Forecast, by Country/Sub-region
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Europe Soft Tissue Market Value Share and Attractiveness Analysis, by Product Type
11.5. Europe Soft Tissue Market Forecast, by Product Type
11.5.1. Cartilage Allografts
11.5.2. Tendon Allografts
11.5.3. Achilles Tendon
11.5.3.1. Patellar Tendon
11.5.3.2. Others
11.5.3.3. Meniscus
11.5.4. Ligament Allografts
11.5.4.1. Anterior Cruciate Ligament
11.5.4.2. Medial Collateral ligament
11.5.5. Artificial Cornea
11.5.6. Dental Allografts
11.5.7. Collagen Allografts
11.5.8. Amniotic Allografts
11.6. Europe Soft Tissue Market Value Share and Attractiveness Analysis, by End-user
11.7. Europe Soft Tissue Market Forecast, by End-user
11.7.1. Hospitals
11.7.2. Orthopedic Clinics
11.7.3. Others
12. Asia Pacific Soft Tissue Market Analysis
12.1. Asia Pacific Soft Tissue Market Overview
12.2. Asia Pacific Soft Tissue Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Asia Pacific Soft Tissue Market Forecast, by Country/Sub-region
12.3.1. China
12.3.2. Japan
12.3.3. India
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Asia Pacific Soft Tissue Market Value Share and Attractiveness Analysis, by Product Type
12.5. Asia Pacific Soft Tissue Market Forecast, by Product Type
12.5.1. Cartilage Allografts
12.5.2. Tendon Allografts
12.5.2.1. Achilles Tendon
12.5.2.2. Patellar Tendon
12.5.2.3. Others
12.5.3. Meniscus
12.5.4. Ligament Allografts
12.5.4.1. Anterior Cruciate Ligament
12.5.4.2. Medial Collateral Ligament
12.5.5. Artificial Cornea
12.5.6. Dental Allografts
12.5.7. Collagen Allografts
12.5.8. Amniotic Allografts
12.6. Asia Pacific Soft Tissue Market Value Share and Attractiveness Analysis, by End-user
12.7. Asia Pacific Soft Tissue Market Forecast, by End-user
12.7.1. Hospitals
12.7.2. Orthopedic Clinics
12.7.3. Others
13. Latin America Soft Tissue Market Analysis
13.1. Latin America Soft Tissue Market Overview
13.2. Latin America Soft Tissue Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Latin America Soft Tissue Market Forecast, by Country/Sub-region
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Latin America Soft Tissue Market Value Share and Attractiveness Analysis, by Product Type
13.5. Latin America Soft Tissue Market Forecast, by Product Type
13.5.1. Cartilage Allografts
13.5.2. Tendon Allografts
13.5.2.1. Achilles Tendon
13.5.2.2. Patellar Tendon
13.5.2.3. Others
13.5.3. Meniscus
13.5.4. Ligament Allografts
13.5.4.1. Anterior Cruciate Ligament
13.5.4.2. Medial Collateral Ligament
13.5.5. Artificial Cornea
13.5.6. Dental Allografts
13.5.7. Collagen Allografts
13.5.8. Amniotic Allografts
13.6. Latin America Soft Tissue Market Value Share and Attractiveness Analysis, by End-user
13.7. Latin America Soft Tissue Market Forecast, by End-user
13.7.1. Hospitals
13.7.2. Orthopedic Clinics
13.7.3. Others
14. Middle East & Africa Soft Tissue Market Analysis
14.1. Middle East & Africa Soft Tissue Market Overview
14.2. Middle East & Africa Soft Tissue Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.3. Middle East & Africa Soft Tissue Market Forecast, by Country/Sub-region
14.3.1. South Africa
14.3.2. GCC countries
14.3.3. Rest of Middle East & Africa
14.4. Middle East & Africa Soft Tissue Market Value Share and Attractiveness Analysis, by Product Type
14.5. Middle East & Africa Soft Tissue Market Forecast, by Product Type
14.5.1. Cartilage Allografts
14.5.2. Tendon Allografts
14.5.2.1. Achilles Tendon
14.5.2.2. Patellar Tendon
14.5.2.3. Others
14.5.3. Meniscus
14.5.4. Ligament Allografts
14.5.4.1. Anterior Cruciate Ligament
14.5.4.2. Medial Collateral Ligament
14.5.5. Artificial Cornea
14.5.6. Dental Allografts
14.5.7. Collagen Allografts
14.5.8. Amniotic Allografts
14.6. Middle East & Africa Soft Tissue Market Value Share and Attractiveness Analysis, by End-user
14.7. Middle East & Africa Soft Tissue Market Forecast, by End-user
14.7.1. Hospitals
14.7.2. Orthopedic Clinics
14.7.3. Others
15. Competition Landscape
15.1. Competition Matrix
15.2. Company Profiles
15.2.1. Corneat Vision
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. SWOT Analysis
15.2.1.4. Strategic Overview
15.2.2. LinkoCare Life Sciences AB.
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. SWOT Analysis
15.2.2.4. Strategic Overview
15.2.3. Presbia plc
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. SWOT Analysis
15.2.3.4. Strategic Overview
15.2.4. Bone Bank Allografts
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. SWOT Analysis
15.2.4.4. Strategic Overview
15.2.5. MTF Biologics
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. SWOT Analysis
15.2.5.4. Strategic Overview
15.2.6. CONMED Corporation
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. Financial Overview
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. AlloSource
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. SWOT Analysis
15.2.7.4. Strategic Overview
15.2.8. Arthrex, Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. SWOT Analysis
15.2.8.4. Strategic Overview
15.2.9. Zimmer Biomet Holdings, Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. Financial Overview
15.2.9.4. SWOT Analysis
15.2.9.5. Strategic Overview
15.2.10. RTI Surgical, Inc.
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Product Portfolio
15.2.10.3. Financial Overview
15.2.10.4. SWOT Analysis
15.2.10.5. Strategic Overview
List of Tables
Table 01: Pricing Analysis, by Cartilage Allografts
Table 02: Pricing Analysis, by Ligament Allografts
Table 03: Pricing Analysis, by Meniscus
Table 04: Pricing Analysis, by Tendon Allografts
Table 05: Pricing Analysis, by Artificial Cornea
Table 06: Global Soft Tissue Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 07: Global Soft tissue Market Value (US$ Mn) Forecast, by Ligament Allografts, 2017–2031
Table 08: Global Soft tissue Market Value (US$ Mn) Forecast, by Tendon Allografts, 2017–2031
Table 09: Global Soft Tissue Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 10: Global Soft Tissue Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 11: North America Soft tissue Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 12: North America Soft tissue Market Size (US$ Mn) Forecast, by Product Type, 2017–2031
Table 13: North America Soft tissue Market Size (US$ Mn) Forecast, by Ligament Allografts, 2017–2031
Table 14: North America Soft tissue Market Size (US$ Mn) Forecast, by Tendon Allografts, 2017–2031
Table 15: North America Soft tissue Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 16: Europe Soft tissue Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Europe Soft tissue Market Size (US$ Mn) Forecast, by Product Type, 2017–2031
Table 18: Europe Soft tissue Market Size (US$ Mn) Forecast, by Ligament Allografts, 2017–2031
Table 19: Europe Soft tissue Market Size (US$ Mn) Forecast, by Tendon Allografts, 2017–2031
Table 20: Europe Soft tissue Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Asia Pacific Soft tissue Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Asia Pacific Soft tissue Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 23: Asia Pacific Soft tissue Market Size (US$ Mn) Forecast, by Ligament Allografts, 2017–2031
Table 24: Asia Pacific Soft tissue Market Size (US$ Mn) Forecast, by Tendon Allografts, 2017–2031
Table 25: Asia Pacific Soft tissue Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 26: Latin America Soft tissue Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Latin America Soft tissue Market Size (US$ Mn) Forecast, by Product Type, 2017–2031
Table 28: Latin America Soft tissue Market Size (US$ Mn) Forecast, by Ligament Allografts, 2017–2031
Table 29: Latin America Soft tissue Market Size (US$ Mn) Forecast, by Tendon Allografts, 2017–2031
Table 30: Latin America Soft tissue Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 31: Middle East & Africa Soft Tissue Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 32: Middle East & Africa Soft Tissue Market Size (US$ Mn) Forecast, by Product Type, 2017–2031
Table 33: Middle East & Africa Soft Tissue Market Size (US$ Mn) Forecast, by Ligament Allografts, 2017–2031
Table 34: Middle East & Africa Soft Tissue Market Size (US$ Mn) Forecast, by Tendon Allografts, 2017–2031
Table 35: Middle East & Africa Soft Tissue Market Size (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Soft Tissue Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Soft Tissue Market Value Share, by Product Type, 2020
Figure 03: Global Soft Tissue Market Value Share, by End-user, 2020
Figure 04: Global Soft Tissue Market Value Share, by Region, 2020
Figure 05: Global Soft Tissue Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 06: Global Soft Tissue Market Value (US$ Mn), by Cartilage Allografts, 2017–2031
Figure 07: Global Soft Tissue Market Value (US$ Mn), by Tendon Allografts, 2017–2031
Figure 08: Global Soft Tissue Market Value (US$ Mn), by Meniscus, 2017–2031
Figure 09: Global Soft Tissue Market Value (US$ Mn), by Ligament Allografts, 2017–2031
Figure 10: Global Soft Tissue Market Value (US$ Mn), by Artificial Cornea, 2017–2031
Figure 11: Global Soft Tissue Market Value (US$ Mn), by Dental Allografts, 2017–2031
Figure 12: Global Soft Tissue Market Value (US$ Mn), by Artificial Cornea, 2017–2031
Figure 13: Global Soft Tissue Market Value (US$ Mn), by Amniotic Allografts, 2017–2031
Figure 14: Global Soft Tissue Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 15: Global Soft Tissue Market Value Share Analysis, by End-user, 2020 and 2031
Figure 16: Global Soft Tissue Market Value (US$ Mn), by Hospitals, 2017–2031
Figure 17: Global Soft Tissue Market Value (US$ Mn), by Orthopedic Clinics, 2017–2031
Figure 18: Global Soft Tissue Market Value (US$ Mn), by Others, 2017–2031
Figure 19: Global Soft Tissue Market Attractiveness Analysis, by End-user, 2021–2031
Figure 20: Global Soft Tissue Market Value Share Analysis, by Region, 2020 and 2031
Figure 21: Global Soft Tissue Market Attractiveness Analysis, by Region, 2021-2031
Figure 22: North America Soft tissue Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 23: North America Soft tissue Market Value Share (%), by Country, 2020 and 2031
Figure 24: North America Soft tissue Market Attractiveness Analysis, by Country, 2021–2031
Figure 25: North America Soft tissue Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 26: North America Soft tissue Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 27: North America Soft tissue Market Value Share Analysis, by End-user, 2020 and 2031
Figure 28: North America Soft tissue Market Attractiveness Analysis, by End-user, 2021–2031
Figure 29: Europe Soft tissue Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 30: Europe Soft tissue Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 31: Europe Soft tissue Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 32: Europe Soft tissue Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 33: Europe Soft tissue Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 34: Europe Soft tissue Market Value Share Analysis, by End-user, 2020 and 2031
Figure 35: Europe Soft tissue Market Attractiveness Analysis, by End-user, 2021–2031
Figure 36: Asia Pacific Soft tissue Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 37: Asia Pacific Soft tissue Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 38: Asia Pacific Soft tissue Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 39: Asia Pacific Soft tissue Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 40: Asia Pacific Soft tissue Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 41: Asia Pacific Soft tissue Market Value Share Analysis, by End-user, 2020 and 2031
Figure 42: Asia Pacific Soft tissue Market Attractiveness Analysis, by End-user, 2021–2031
Figure 43: Latin America Soft tissue Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 44: Latin America Soft tissue Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 45: Latin America Soft tissue Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 46: Latin America Soft tissue Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 47: Latin America Soft tissue Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 48: Latin America Soft tissue Market Value Share Analysis, by End-user, 2020 and 2031
Figure 49: Latin America Soft tissue Market Attractiveness Analysis, by End-user, 2021–2031
Figure 50: Middle East & Africa Soft Tissue Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 51: Middle East & Africa Soft Tissue Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 52: Middle East & Africa Soft Tissue Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 53: Middle East & Africa Soft Tissue Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 54: Middle East & Africa Soft Tissue Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 55: Middle East & Africa Soft Tissue Market Value Share Analysis, by End-user, 2020 and 2031
Figure 56: Middle East & Africa Soft Tissue Market Attractiveness Analysis, by End-user, 2021–2031
Figure 57: CONMED Corporation, Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 58: CONMED Corporation, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 59: CONMED Corporation, Breakdown of Net Sales (%), by Region, 2020
Figure 60: CONMED Corporation, Breakdown of Net Sales (%), by Business Segment, 2020
Figure 61: Zimmer Biomet Holdings, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 62: Zimmer Biomet Holdings, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 63: Zimmer Biomet Holdings, Inc., Breakdown of Net Sales (%), by Region, 2020
Figure 64: Zimmer Biomet Holdings, Inc., Breakdown of Net Sales (%), by Product Category, 2020
Figure 65: RTI Surgical, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 66: RTI Surgical, Inc., R& D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Soft Tissue Market
